CompletedPhase 3NCT00639496

Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Zambon SpA
Principal Investigator: M. Demedts, MD
U.Z.-Gasthuisberg, Leuven, Belgium
Intervention: n-acetylcysteine(drug)
Enrollment: 184 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2000 – 2003

Study locations (7)

U.Z. Ghent, Ghent, Belgium
Hôpital A. Calmette, Lille, France
Klinikum Grosshadern, Munich, Germany
U.O. di Pneumologia-Ospedale, Arezzo, Italy
Stichting St. Antonius Ziekenhuis, Nieuwegein, Netherlands
Hospital Universitario Virgen del Rocío, Seville, Spain
The University of Edinburgh-Medical School, Edinburgh, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00639496 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials